Abstract
In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-α), interleukin one beta (IL-1β), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn’s disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn’s disease.
Keywords: APA microcapsules, in vivo study, molecular markers, Crohn’s disease, thalidomide.
Current Drug Delivery
Title:Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice
Volume: 11 Issue: 1
Author(s): Marc Fakhoury, Michael Coussa-Charley, Hani Al-Salami, Imen Kahouli and Satya Prakash
Affiliation:
Keywords: APA microcapsules, in vivo study, molecular markers, Crohn’s disease, thalidomide.
Abstract: In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-α), interleukin one beta (IL-1β), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn’s disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn’s disease.
Export Options
About this article
Cite this article as:
Fakhoury Marc, Coussa-Charley Michael, Al-Salami Hani, Kahouli Imen and Prakash Satya, Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice, Current Drug Delivery 2014; 11 (1) . https://dx.doi.org/10.2174/156720181101140212170025
DOI https://dx.doi.org/10.2174/156720181101140212170025 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress: Major Threat in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Mechanism-Based Inhibitors from Phytomedicine: Risks of Hepatotoxicity and their Potential Hepatotoxic Substructures
Current Drug Metabolism The Conduct of Drug Metabolism Studies Considered Good Practice (I): Analytical Systems and In Vivo Studies
Current Drug Metabolism Development of Yeast Molecular Display Systems Focused on Therapeutic Proteins, Enzymes, and Foods: Functional Analysis of Proteins and its Application to Bioconversion
Recent Patents on Biotechnology Clinical Proteomics of Breast Cancer
Current Genomics Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry Towards Characteristics of Photodynamic Drugs Specifically Aimed at Microvascular Diseases
Mini-Reviews in Medicinal Chemistry Glucosidase II and MRH-Domain Containing Proteins in the Secretory Pathway
Current Protein & Peptide Science Boronate-Based Fluorescent Probes as a Prominent Tool for H<sub>2</sub>O<sub>2</sub> Sensing and Recognition
Current Medicinal Chemistry Proteomic Studies Using Microarrays
Current Proteomics Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands
Current Medicinal Chemistry Synthesis of Novel Benzoquinones with Anti-Inflammatory Activity
Letters in Drug Design & Discovery Charge Deficient Analogues of the Natural Polyamines
Current Pharmaceutical Design Tyrosinase Electrochemical Biosensors Monitoring Medicinally Significant Substances
Current Medicinal Chemistry Sol-gel Chemistry in Medicinal Science
Current Medicinal Chemistry Targeting NO/cGMP Signaling in the CNS for Neurodegeneration and Alzheimer’s Disease
Current Medicinal Chemistry Integrated Analysis of mRNA-seq and miRNA-seq to Identify c-MYC, YAP1 and miR-3960 as Major Players in the Anticancer Effects of Caffeic Acid Phenethyl Ester in Human Small Cell Lung Cancer Cell Line
Current Gene Therapy Prostate Cancer Prevention in the Developing World - What are we Waiting for?
Current Pharmacogenomics and Personalized Medicine Cancer Chemopreventive Agents Discovered by Activity-Guided Fractionation: An Update
Current Organic Chemistry Recent Survey on Nanosuspension: A Patent Overview
Recent Patents on Drug Delivery & Formulation